Control of adaptive immunity by pattern recognition receptors
(1) Carroll SL (2) Pasare C (3) Barton GM
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer
(1) Haiderali A (2) Huang M (3) Pan W (4) Akers KG (5) Maciel D (6) Frederickson AM
(1) Haiderali A (2) Huang M (3) Pan W (4) Akers KG (5) Maciel D (6) Frederickson AM
Author Info: (1) Center for Observational & Real-World Evidence; Merck & Co., Inc., Rahway, NJ 07065, USA. (2) Center for Observational & Real-World Evidence; Merck & Co., Inc., Rahway, NJ 0706
Author Info: (1) Center for Observational & Real-World Evidence; Merck & Co., Inc., Rahway, NJ 07065, USA. (2) Center for Observational & Real-World Evidence; Merck & Co., Inc., Rahway, NJ 07065, USA. (3) Center for Observational & Real-World Evidence; Merck & Co., Inc., Rahway, NJ 07065, USA. (4) PRECISIONheor; New York, NY 11203, USA. (5) PRECISIONheor; New York, NY 11203, USA. (6) PRECISIONheor; New York, NY 11203, USA.
Citation: Future Oncol 2024 Apr 10 Epub04/10/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38597713
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study
(1) Elez E (2) Cubillo A (3) Alfonso PG (4) Middleton MR (5) Chau I (6) Alkuzweny B (7) Alcasid A (8) Zhang X (9) Van Cutsem E
(1) Elez E (2) Cubillo A (3) Alfonso PG (4) Middleton MR (5) Chau I (6) Alkuzweny B (7) Alcasid A (8) Zhang X (9) Van Cutsem E
Author Info: (1) Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autnoma de Barcelona, Barcelona, Spain. meelez@vhio.net. (2
Author Info: (1) Medical Oncology Department, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autnoma de Barcelona, Barcelona, Spain. meelez@vhio.net. (2) Centro Integral, Oncolgico Clara Campal, HM CIOCC, Madrid, Spain. Facultad HM Hospitales de Ciencias de La Salud UCJC, 28050, Madrid, Spain. (3) Medical Oncology Service, Hospital General Universitario Gregorio Maran, Instituto de Investigacin Sanitaria Gregorio Maran (IiSGM), Universidad Complutense, Madrid, Spain. (4) Department of Oncology, NIHR Biomedical Research Centre, University of Oxford, Oxford, UK. (5) Gastrointestinal Unit, Royal Marsden Hospital, London & Surrey, UK. (6) Formerly Pfizer, Inc, San Diego, CA, USA. (7) Pfizer Inc, Collegeville, PA, USA. (8) Pfizer, Inc, New York, NY, USA. (9) University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
Citation: BMC Cancer 2024 Apr 11 24:446 Epub04/11/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38600471
The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases
(1) Salminen A
(1) Salminen A
Author Info: (1) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. antero.salminen@uef.fi.
Author Info: (1) Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. antero.salminen@uef.fi.
Citation: J Mol Med (Berl) 2024 Apr 11 Epub04/11/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38600305
A pan-cancer analysis of the microbiome in metastatic cancer
(1) Battaglia TW (2) Mimpen IL (3) Traets JJH (4) van Hoeck A (5) Zeverijn LJ (6) Geurts BS (7) de Wit GF (8) No M (9) Hofland I (10) Vos JL (11) Cornelissen S (12) Alkemade M (13) Broeks A (14) Zuur CL (15) Cuppen E (16) Wessels L (17) van de Haar J (18) Voest E
(1) Battaglia TW (2) Mimpen IL (3) Traets JJH (4) van Hoeck A (5) Zeverijn LJ (6) Geurts BS (7) de Wit GF (8) No M (9) Hofland I (10) Vos JL (11) Cornelissen S (12) Alkemade M (13) Broeks A (14) Zuur CL (15) Cuppen E (16) Wessels L (17) van de Haar J (18) Voest E
Author Info: (1) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Division of Molecular Carcinogenesis, the Netherlands Cancer
Author Info: (1) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (2) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (3) Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (4) Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. (5) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (6) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (7) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (8) Department of Pathology, Antoni van Leeuwenhoek/the Netherlands Cancer Institute, Amsterdam, the Netherlands. (9) Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (10) Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (11) Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (12) Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (13) Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (14) Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands. (15) Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht 3584CX, the Netherlands; Hartwig Medical Foundation, Science Park, Amsterdam 1098XH, the Netherlands. (16) Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Faculty of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands. (17) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. (18) Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. Electronic address: e.voest@nki.nl.
Citation: Cell 2024 Apr 5 Epub04/05/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38599211
Vaccine adjuvants: Tailoring innate recognition to send the right message
(1) Lavelle EC (2) McEntee CP
(1) Lavelle EC (2) McEntee CP
Author Info: (1) School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. Electronic address: lavellee@tcd.ie. (2) School of Bioche
Author Info: (1) School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland. Electronic address: lavellee@tcd.ie. (2) School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Citation: Immunity 2024 Apr 9 57:772-789 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38599170
Myeloid C-type lectin receptors in innate immune recognition
(1) Reis E Sousa C (2) Yamasaki S (3) Brown GD
(1) Reis E Sousa C (2) Yamasaki S (3) Brown GD
Author Info: (1) Immunobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK. Electronic address: caetano@crick.ac.uk. (2) Molecular Immunology, Research Institute
Author Info: (1) Immunobiology Laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London, UK. Electronic address: caetano@crick.ac.uk. (2) Molecular Immunology, Research Institute for Microbial Diseases, Immunology Frontier Research Center (IFReC), Osaka University, Suita 565-0871, Japan. Electronic address: yamasaki@biken.osaka-u.ac.jp. (3) MRC Centre for Medical Mycology at the University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, UK. Electronic address: gordon.brown@exeter.ac.uk.
Citation: Immunity 2024 Apr 9 57:700-717 Epub
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38599166
Tags:
Bispecific antibodies tethering innate receptors induce human tolerant-dendritic cells and regulatory T cells
(1) Lamendour L (2) Gilotin M (3) Deluce-Kakwata Nkor N (4) Lakhrif Z (5) Meley D (6) Poupon A (7) Laboute T (8) di Tommaso A (9) Pin JJ (10) Mulleman D (11) Le Mldo G (12) Aubrey N (13) Watier H (14) Velge-Roussel F
(1) Lamendour L (2) Gilotin M (3) Deluce-Kakwata Nkor N (4) Lakhrif Z (5) Meley D (6) Poupon A (7) Laboute T (8) di Tommaso A (9) Pin JJ (10) Mulleman D (11) Le Mldo G (12) Aubrey N (13) Watier H (14) Velge-Roussel F
Author Info: (1) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (2) EA7501, Groupe Innovation
Author Info: (1) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (2) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (3) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (4) Infectiologie et Sant Publique (ISP) UMR 1282, INRAE, Team BioMAP, Universit de Tours, Tours, France. (5) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (6) institut de recherche pour l'agriculture, l'alimentation et 'environnement (INRAE) UMR 0085, centre de recherche scientifique (CNRS) UMR 7247, Physiologie de la Reproduction et des Comportements, Universit de Tours, Tours, France. MAbSilico, Tours, France. (7) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (8) Infectiologie et Sant Publique (ISP) UMR 1282, INRAE, Team BioMAP, Universit de Tours, Tours, France. (9) Dendritics, Lyon, France. (10) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. Service de Rhumatologie, Centre Hospitalo-Universitaire (CHRU) de Tours, Tours, France. (11) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. Service de Rhumatologie, Centre Hospitalo-Universitaire (CHRU) de Tours, Tours, France. (12) Infectiologie et Sant Publique (ISP) UMR 1282, INRAE, Team BioMAP, Universit de Tours, Tours, France. (13) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France. (14) EA7501, Groupe Innovation et Ciblage Cellulaire, Team Fc Rcepteurs, Anticorps et MicroEnvironnement (FRAME), Universit de Tours, Tours, France.
Citation: Front Immunol 2024 15:1369117 Epub03/26/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38601165
Lack of shared neoantigens in prevalent mutations in cancer
(1) Ragone C (2) Cavalluzzo B (3) Mauriello A (4) Tagliamonte M (5) Buonaguro L
(1) Ragone C (2) Cavalluzzo B (3) Mauriello A (4) Tagliamonte M (5) Buonaguro L
Author Info: (1) Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS - "Fondazione Pascale", Via Mariano Semmola, 52, 80131, Naples, Italy. (2) Lab of Innovative Immun
Author Info: (1) Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS - "Fondazione Pascale", Via Mariano Semmola, 52, 80131, Naples, Italy. (2) Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS - "Fondazione Pascale", Via Mariano Semmola, 52, 80131, Naples, Italy. (3) Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS - "Fondazione Pascale", Via Mariano Semmola, 52, 80131, Naples, Italy. (4) Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS - "Fondazione Pascale", Via Mariano Semmola, 52, 80131, Naples, Italy. m.tagliamonte@istitutotumori.na.it. (5) Lab of Innovative Immunological Models Unit, Istituto Nazionale Tumori, IRCCS - "Fondazione Pascale", Via Mariano Semmola, 52, 80131, Naples, Italy. l.buonaguro@istitutotumori.na.it.
Citation: J Transl Med 2024 Apr 10 22:344 Epub04/10/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38600547
FOXO1 is a master regulator of memory programming in CAR T cells
(1) Doan AE (2) Mueller KP (3) Chen AY (4) Rouin GT (5) Chen Y (6) Daniel B (7) Lattin J (8) Markovska M (9) Mozarsky B (10) Arias-Umana J (11) Hapke R (12) Jung IY (13) Wang A (14) Xu P (15) Klysz D (16) Zuern G (17) Bashti M (18) Quinn PJ (19) Miao Z (20) Sandor K (21) Zhang W (22) Chen GM (23) Ryu F (24) Logun M (25) Hall J (26) Tan K (27) Grupp SA (28) McClory SE (29) Lareau CA (30) Fraietta JA (31) Sotillo E (32) Satpathy AT (33) Mackall CL (34) Weber EW
(1) Doan AE (2) Mueller KP (3) Chen AY (4) Rouin GT (5) Chen Y (6) Daniel B (7) Lattin J (8) Markovska M (9) Mozarsky B (10) Arias-Umana J (11) Hapke R (12) Jung IY (13) Wang A (14) Xu P (15) Klysz D (16) Zuern G (17) Bashti M (18) Quinn PJ (19) Miao Z (20) Sandor K (21) Zhang W (22) Chen GM (23) Ryu F (24) Logun M (25) Hall J (26) Tan K (27) Grupp SA (28) McClory SE (29) Lareau CA (30) Fraietta JA (31) Sotillo E (32) Satpathy AT (33) Mackall CL (34) Weber EW
Author Info: (1) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (2) Department of Pediatrics, Perelman School of Medicine,
Author Info: (1) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (2) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (3) Department of Pathology, Stanford University, Stanford, CA, USA. Department of Bioengineering, Stanford University, Stanford, CA, USA. Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. (4) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (5) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (6) Department of Pathology, Stanford University, Stanford, CA, USA. Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA. Department of Genetics, Stanford University, Stanford, CA, USA. Genentech, South San Francisco, CA, USA. (7) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (8) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (9) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (10) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (11) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (12) Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (13) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (14) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (15) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (16) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (17) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (18) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (19) Department of Genetics, Stanford University, Stanford, CA, USA. (20) Department of Pathology, Stanford University, Stanford, CA, USA. Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. (21) Department of Pathology, Stanford University, Stanford, CA, USA. Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. (22) Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (23) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (24) Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (25) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (26) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (27) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (28) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. (29) Department of Pathology, Stanford University, Stanford, CA, USA. Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. (30) Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. (31) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (32) Department of Pathology, Stanford University, Stanford, CA, USA. Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. (33) Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. cmackall@stanford.edu. Department of Pediatrics, Stanford University, Stanford, CA, USA. cmackall@stanford.edu. Department of Medicine, Stanford University, Stanford, CA, USA. cmackall@stanford.edu. (34) Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. weberew@chop.edu. Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. weberew@chop.edu. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. weberew@chop.edu. Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. weberew@chop.edu. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. weberew@chop.edu. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. weberew@chop.edu.
Citation: Nature 2024 Apr 10 Epub04/10/2024
Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/38600391